SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
gmc
Lv5
1070 积分
2024-04-25 加入
最近求助
最近应助
互助留言
Epinephrine treatment of food-induced and other cause anaphylaxis in United States and Canadian Emergency Departments: a systematic review and meta-analysis
20天前
已完结
Anaphylaxis in outpatients: A 5‐year retrospective study on incidence and clinical characteristics at a university hospital in Wuhan, China
27天前
已关闭
Prevalence and Trend of Biopsy-Proven IgA Nephropathy in China: A Systematic Review
1个月前
已关闭
Long-Term Outcomes in IgA Nephropathy
1个月前
已完结
Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study
1个月前
已完结
Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study
1个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
1个月前
已完结
Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy
1个月前
已关闭
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia
2个月前
已完结
没有进行任何应助
不需要了【积分已退回】
27天前
不需要了【积分已退回】
1个月前
已下载【积分已退回】
1个月前
重新输入【积分已退回】
2个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论